SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Piramal Pharma informs about grant of stock options

26 Jul 2024 Evaluate

Pursuant to Regulation 30 read with Schedule III to the SEBI Listing Regulations, Piramal Pharma has informed that the Nomination and Remuneration Committee of the Board of Directors of the Company at its meeting held on Friday, 26th July, 2024 approved grant of 4,830,836 stock options under the Plan 2022. The disclosure as required under Regulation 30 of SEBI Listing Regulations is enclosed as Annexure-1.

The above information is a part of company’s filings submitted to BSE.


Piramal Pharma Share Price

165.60 1.80 (1.10%)
24-Apr-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1618.50
Dr. Reddys Lab 1312.40
Cipla 1295.00
Zydus Lifesciences 930.00
Lupin 2285.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×